Skip to content
OpenCapital
Get started

Rani Therapeutics Holdings, Inc. RANI Q4 2025 Annual earnings

Reported March 26, 2026 · After market close

Revenue$1.5MMiss by $3.5M
EPS-$0.07Miss by $0.04
Revenue estimate$5.0M
EPS estimate-$0.03

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$925.0K
EPS estimate-$0.05

Versus estimates

Revenue

Q1 2026$1.7MBeat by $583.0K
Q4 2025$1.5MMiss by $3.5M
Q1 2025$172.0KQ4 2024$1.0M

Diluted EPS

Q1 2026-$0.04Beat by $0.02
Q4 2025-$0.07Miss by $0.04
Q3 2025-$0.12Miss by $0.03Q2 2025-$0.18Beat by $0.01Q1 2025-$0.22In lineQ4 2024-$0.27Miss by $0.03

Ask the moment Rani Therapeutics Holdings, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Rani Therapeutics Holdings, Inc. report Q4 2025 earnings?
Rani Therapeutics Holdings, Inc. (RANI) reported Q4 2025 earnings on March 26, 2026 after market close.
What were Rani Therapeutics Holdings, Inc.'s Q4 2025 revenue and EPS?
Rani Therapeutics Holdings, Inc. reported revenue of $1.5M and eps of $-0.07 for Q4 2025.
Did Rani Therapeutics Holdings, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $5.0M by $3.5M. EPS missed the consensus estimate of $-0.03 by $0.04.
How did Rani Therapeutics Holdings, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 42.1% from $1.0M a year earlier and eps grew 74.1% from $-0.27.
Where can I find Rani Therapeutics Holdings, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-126240) and the 10-K periodic report (0001193125-26-126417) directly on SEC EDGAR. The filing index links above go to sec.gov.